Azacitidine

Drug Profile

Azacitidine

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; CC-486; Ladakamycin; NS-17; NSC-102816; U-18496; Vidaza

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Nippon Shinyaku; Pfizer; University of Colorado at Denver; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Breast cancer; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Solid tumours
  • Phase I Lymphoma
  • Phase Unknown Head and neck cancer

Most Recent Events

  • 11 Jan 2017 Investigation in Head and neck cancer in USA (Parenteral) before January 2017
  • 11 Jan 2017 AstraZeneca and Massachusetts General Hospital plan the phase Ib/II Rescue study for Head and neck cancer (Recurrent, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03019003)
  • 05 Dec 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top